NEW YORK and MAINZ, GERMANY, September 28, 2022 —Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children 5 through 11 years of age.
We’re not the first business to discover how technology increases diversity, but we’ve been among the first to adopt it and make it work.
Innovation isn’t easy. Otherwise everyone could do it.
It takes many talented people putting their heads together to find inventive ways around some of the world’s biggest and toughest challenges. But, on top of being talented, everyone needs to be talented in different ways.
At Pfizer, we’re transforming and redefining ‘growth’ for our colleagues. To live and deliver on our purpose: breakthroughs that change patients’ lives, we need to continually grow ourselves and those around us. Doing this – while thinking big and pursuing bold goals – will help us to bring medicines and vaccines forward that can radically alter the course of a disease. We now see growth as a part of our DNA: We grow every day. In practice, this means promoting equitable growth opportunities for all our colleagues.
NEW YORK, September 24, 2022 – Pfizer Inc. (NYSE: PFE) – I wanted to let you know that I have tested positive for COVID. I’m feeling well and symptom free. I’ve not had the new bivalent booster yet, as I was following CDC guidelines to wait three months since my previous COVID case which was back in mid-August. While we’ve made great progress, the virus is still with us.
Media Relations:
+1 (212) 733-1226
PfizerMediaRelations@Pfizer.com
We are honored to share the 16th anniversary edition of our Pride Journal - a platform where our LGBTQ+ Pfizer Colleagues and allies can share personal experiences of struggles, triumph, and their hope for the future in honor of Pride Month. Read the stories that have provided inspiration to so many:
Former Chief Development Officer
NYHQ
New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. Trial sites will begin to resume enrollment this month, with dosing expected to resume in October.
NEW YORK and MAINZ, GERMANY, SEPT 16, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today an
FOR IMMEDIATE RELEASE -NEW YORK, NY., August 22, 2022
Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Propofol Injectable Emulsion (containing benzyl alcohol),
100mL Single Patient Use Glass Fliptop Vial; lot EA7470, to the user level due to visible particulates observed in two vials during annual examination of retention samples.